FRESENIUS MEDICAL CARE

Information

for the Annual General Meeting

of Fresenius Medical Care AG & Co. KGaA

on 16 May 2019

pertaining to Agenda Item 2
(Resolution on the allocation of distributable profit)

Bad Homburg v.d. Höhe, April 2019

Since the founding of the company in 1996, Fresenius Medical Care has increased its dividend on average by 10% every year. Correspondingly, we propose to the AGM a **10% dividend increase to €1.17 per share** for 2018. This would be the 22nd consecutive dividend increase (see attachment 1: dividend development).

If the dividend proposal is accepted by the Annual General Meeting, the total dividend payout for 2018 with around 307 million shares entitled to a dividend (as of December 31, 2018) will amount to around **€359 million**. This represents a payout ratio of around 18%. Based on the adjusted net income 2018, the payout ratio is around 30% (see attachment 2: reconciliation of revenue and earnings).

On top, Fresenius Medical Care has decided to create additional shareholder return through a **share buy-back program.** Under this share buy-back program, which has already started, the company will repurchase shares in a total aggregate amount of up to **€1 billion** over the course of 2019 and 2020.

Also in the future, we want our shareholders to participate adequately in the company's success. Maintaining dividend continuity is important to us. Our dividend proposal targets to balance short-term and long-term shareholder returns. This requires ensuring our financial flexibility in order to pursue our ambitious growth targets. As announced earlier, 2019 will be a year of investments to support Fresenius Medical Care’s further profitable growth. For example, we want to expand home dialysis in North America and we will increasingly invest in developing economies such as China, where we expect above-average growth. In addition, we will invest €100 million in a cost optimization program in 2019.

With these investments we aim to continue the successful path of sustainable growth of total shareholder return in the future.

22ND CONSECUTIVE DIVIDEND INCREASE



[1] Proposed dividend for approval at the AGM on May 16, 2019.

2018: RECONCILIATION ADJUSTMENTS

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES TO THE MOST DIRECTLY COMPARABLE IFRS FINANCIAL MEASURES

	Q4 2018 € million	Q4 2017 € million	2018 € million	2017 € million
Revenue	**4,300**	**4,429**	**16,547**	**17,784**
IFRS 15 Implementation		(100)		(486)
Sound H2 2017[1]		(305)		(559)
Revenue on a comparable basis	**4,300**	**4,024**	**16,547**	**16,739**
VA Agreement[2]		1		(94)
Revenue adjusted	**4,300**	**4,025**	**16,547**	**16,645**
Net income[5]	**425**	**394**	**1,982**	**1,280**
(Gain) loss related to divestitures of Care Coordination activities	17		(673)	
Sound H2 2017[1]		(33)		(38)
2018 FCPA Related Charge	(47)		28	
U.S. Ballot Initiatives[3]	13		40	
Net income[5] on a comparable basis	**408**	**361**	**1,377**	**1,242**
VA Agreement[2]		1		(51)
Natural Disaster Costs[4]		3		11
2017 FCPA Related Charge		200		200
U.S. Tax Reform (excl. Sound H2 2017)[6]	(55)	(240)	(192)	(240)
Net income[5] adjusted	**353**	**325**	**1,185**	**1,162**

[1] Sound H2 2017: contribution of Sound Physicians │ [2] VA Agreement: Agreement with the United States Departments of Veterans Affairs and Justice │ [3] U.S. Ballot Initiatives: contributions to the opposition to the ballot initiatives in the U.S. │ [4] Natural Disaster Costs: three hurricanes and an earthquake │ [5] Attributable to shareholders of FMC AG & Co. KGaA │ [6] U.S. Tax Reform: impacts from U.S. tax reform